Concordant fibroadenoma in a young woman — surveillance, excision triggers and the phyllodes check

Model answer

(A) Surveillance with a concordant triple assessment (4 marks)

• Concordance is the decision: physical examination, sonography and tissue diagnosis agree on benign fibroadenoma, and that combination is effective in distinguishing fibroadenomas from breast cancer — so no discordant arm forces excision.^[14]
• Quote the triple-test accuracy behind definitive management of a palpable lump: overall accuracy 98% with 100% sensitivity, 95.2% specificity and 96.7% positive predictive value — the evidence for acting on concordance rather than repeating biopsies.^[15]
• Justify observation biologically: transformation from fibroadenoma to cancer is rare while regression or resolution is frequent, supporting conservative follow-up — the natural-history reason surveillance is safe.^[14]
• Set explicit excision triggers at the same visit: clinico-radiologic-pathologic discordance, growth, complex or proliferative features or atypia with the fibroadenoma, BIRADS 4 imaging, or informed patient preference — with multidisciplinary discussion where any trigger appears.^[13][16]

(B) Size, phyllodes worry and margins (3 marks)

• Size alone does not book surgery: in 1392 provisionally-fibroadenoma patients the size of the lesion measured by largest diameter was insignificant (p = 0.99), while age, marital status and BIRADS score were significant — and the size of the tumor alone should not be used as an indication for surgical intervention.^[13]
• Worry about phyllodes with rapid growth, larger size, stromal features or cellular fibroepithelial cores: the WHO classification distinguishes benign (grade 1), borderline (grade 2) and malignant (grade 3) phyllodes tumours, with pooled recurrence of 7.1%, 16.7% and 25.1% respectively — a different disease with a different operation.^[16][5]
• State the margin rule if phyllodes is confirmed: the ideal surgical margin should be at least 1 cm in width, refined to in-sano excision for grades 1 to 2 and 10-mm margins for grade 2 disease — with no lymph-node evaluation and no systematic mastectomy.^[5][16]

(C) Incidental atypia — risk and prevention (3 marks)

• Reframe atypia as a risk biomarker, not a cancer: atypical hyperplasia carries a 4- to 5-fold risk of breast cancer compared with the general population — against roughly two-fold for hyperplasia of the usual type.^[4]
• Individualise with the Mayo modifiers: relative risk 3.88 overall, rising to 10.35 with three or more foci plus calcifications and 6.76 under age 45, with cumulative incidence approaching 35% at 30 years and very-high-risk status above 50% at 20 years when multifocal disease and calcifications combine.^[2]
• Counsel prevention explicitly: tamoxifen is particularly effective in atypical hyperplasia with more than 70% reduction in the P1 trial and 60% in IBIS-I, and aromatase inhibitors are also highly effective for atypical hyperplasia and lobular carcinoma in situ — while noting there are no published prevention data for hyperplasia of the usual type.^[4]
• Set lifelong bilateral surveillance with risk assessment: risk stays elevated over 20 years, family history does not further increase risk once atypia is established, and the plan leaves clinic with surveillance plus prevention counselling rather than reassurance alone.^[2][4]